Hepatocyte growth factor (HGF) (or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.

Scope of the Report:
The application of hepatocyte growth factor includes oncology, cardiovascular, central nervous system, hematological disorders and others, and the proportion of R&D Investment for oncology in 2017 is about 36%, and the proportion is in decreasing trend from 2012 to 2016.
Asia Pacific will be the largest market, which will occupy nearly 62% market share in 2030. Following Asia Pacific, North America will be the second largest market with the consumption market share of 25% in 2030.
The worldwide market for Hepatocyte Growth Factor is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new study.
This report focuses on the Hepatocyte Growth Factor in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
ViroMed
AnGes MG
M3 Biotechnology
AVEO Pharmaceuticals
Molecular Partners
Yooyoung Pharm
F-star
Galaxy Biotech
Kringle Pharma

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Type I
Type II

Market Segment by Applications, can be divided into
Oncology
Cardiovascular
Central Nervous System
Hematological Disorders
Others

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hepatocyte Growth Factor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hepatocyte Growth Factor, with price, sales, revenue and global market share of Hepatocyte Growth Factor in 2017 and 2018.
Chapter 3, the Hepatocyte Growth Factor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hepatocyte Growth Factor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Hepatocyte Growth Factor market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Hepatocyte Growth Factor sales channel, distributors, customers, research findings and conclusion, appendix and data source.